Chemistry:Dezandrodeg

From HandWiki

Dezandrodeg (INN, USAN; developmental code names BMS-986365 and CC-94676) is an antiandrogen which is under development for the treatment of prostate cancer.[1][2][3][4] It is taken orally.[1] The drug acts as a dual androgen receptor antagonist and androgen receptor degrader.[1][2][3][4] It is under development by Celgene Corporation and Bristol-Myers Squibb.[1][2] As of June 2026, dezandrodeg is in phase 3 clinical trials for prostate cancer.[1][2] It was also under development for the treatment of solid tumors, but no recent development has been reported.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Celgene Corporation". 15 June 2026. https://adisinsight.springer.com/drugs/800059096. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on Dezandrodeg with Synapse". 3 July 2026. https://synapse.patsnap.com/drug/bffaf59136574388bb35b88c361a4608. 
  3. ↑ 3.0 3.1 "Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer". Clinical Cancer Research 32 (1): 224–241. January 2026. doi:10.1158/1078-0432.CCR-25-0471. PMID 40788283. 
  4. ↑ 4.0 4.1 "Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365". Journal of Medicinal Chemistry 69 (14): 16346–16362. July 2026. doi:10.1021/acs.jmedchem.6c01590. PMID 42430428. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Dezandrodeg&oldid=4583740"